事件:公司发布2024年度报告,2024年收入达 4.3亿元,合作收入为 3.9亿元,司普奇拜单抗收入0.4 亿元。业绩符合预期。司普奇拜单抗三大适应症上市,放量在即。司普奇拜单抗治疗成人中重度特应性皮炎、慢性鼻窦炎伴鼻息肉及季节性过敏性鼻炎的三项上市申请均获国家药监局批准。此外,司普奇拜单抗用于治疗青少年中重度特应性皮炎的Ⅲ期临床研究已完成入组,并于2024 年5月启动了一项评价司普奇拜单抗...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.